A Reversibly Thermoresponsive, Theranostic Nanoemulgel for Tacrolimus Delivery to Activated Macrophages: Formulation and In Vitro Validation

Despite long-term immunosuppression, organ transplant recipients face the risk of immune rejection and graft loss. Tacrolimus (TAC, FK506, Prograf(®)) is an FDA-approved keystone immunosuppressant for preventing transplant rejection. However, it undergoes extensive first-pass metabolism and has a na...

Descripción completa

Detalles Bibliográficos
Autores principales: Vichare, Riddhi, Crelli, Caitlin, Liu, Lu, Das, Amit Chandra, McCallin, Rebecca, Zor, Fatih, Kulahci, Yalcin, Gorantla, Vijay S., Janjic, Jelena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610217/
https://www.ncbi.nlm.nih.gov/pubmed/37896130
http://dx.doi.org/10.3390/pharmaceutics15102372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610217/
https://www.ncbi.nlm.nih.gov/pubmed/37896130
http://dx.doi.org/10.3390/pharmaceutics15102372

Ejemplares similares